Tag: olanzapine
MedinCell – Partner Teva provides 2024 sales forecast for UZEDY™ and provides update on long-acting injectable olanzapine treatment candidate – 01/31/2024 at 10:00 p.m.
· UZEDY revenue forecast for Teva in 2024: ~$80 million · Ongoing phase 3 of Olanzapine LAI: l675 patients (recruitment completed), 62% of 3,600 planned injections completed, no PDSS (post-injection…
MedinCell – Partner Teva announces the end of patient recruitment in the phase 3 clinical study of mdc-TJK, long-acting injectable treatment of olanzapine – 01/09/2024 at 7:20 p.m.
Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the…